ArticlePloS one2025
Preliminary study on metabolite differences between two obesity syndromes based on Q Exactive liquid chromatography-tandem mass spectrometry metabolomics.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to traditional Chinese medicine, based on the pathogenesis, clinical manifestation, and treatment, obesity can be classified into two broad types, namely, "shi obesity" and "xu obesity." The aim of this study was to explore the differences in metabolite levels between these two types of obesity.
methodsQ Exactive liquid chromatography-tandem mass spectrometry was used to analyze the metabolites in the sera of 30 healthy adults, 30 adults with shi obesity, and 30 adults with xu obesity. Possible metabolic pathways associated with biological alterations were identified using the Human Metabolome Database and Kyoto Encyclopedia of Genes and Genomes analyses.
resultsFifteen important potential biomarkers were identified, 14 of which were upregulated. Furthermore, the biomarkers phenylalanine, L-tyrosine, glycerophosphocholine, and LysoPC(O-18:0/0:0) were significantly correlated with both shi and xu obesity. Of note, L-tyrosine and glycerophosphocholine were screened and used as potential biomarkers of shi and xu obesity for the first time.
conclusionThis study verified the differences in serum metabolites associated with shi and xu obesity, demonstrating potential therapeutic strategies for the two types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.